Dedicated to Research Since 1993

Global Thyroid Gland Disorder Treatment Market by Disease Type (Hypothyroidism, Hyperthyroidism) by Administration (Oral, Intravenous) – Business Overview, Analysis and Industry Forecast 2017-2023

 Healthcare and Pharmaceuticals

Report Overview

Global Thyroid Gland Disorder Treatment Market was valued at USD XX Billion in the year 2017. Global Thyroid Gland Disorder Treatment market is further estimated to grow at a CAGR of XX% from 2018 to reach USD XX Billion by the year 2023.

North America region holds the highest market share and is considered as the fastest growing market in the forecasted period. The major factors that drive the growth of the market include an increase in the incidence of thyroid gland disorder, a rise in the number of disease awareness programs

Abbott Laboratories (U.S), Merck & Co. Inc. (U.S), AbbVie Inc. (U.S), Allergan Plc. (Republic of Ireland), GlaxoSmithKline plc (U.K), Lannett Company, Inc. (U.S), Mylan N.V. (U.S), Novartis AG (Switzerland), Pfizer Inc. (U.S), and RLC LABS, Inc. (U.S) are the key players for the Global Thyroid Gland Disorder Treatment market


Increase in the incidence of thyroid gland disorders


Side effects that cause lesser patient adherence


Availability of large pool of undiagnosed patients due to asymptomatic nature of thyroid disorders


Stringent government regulations

The global Thyroid Gland Disorder Treatment market is segmented into disease type, drug type, by route of administration, by distribution channel, and region. Based on the disease type, the market is bifurcated into hypothyroidism and hyperthyroidism. The hypothyroidism segment dominates the market and is expected to grow with XX% CAGR in coming years, owing to the high prevalence of iodine deficiency population worldwide, and is the most commonly occurring thyroid disorder.

Based on a route of administration, the market is classified into oral, intravenous, and others. The oral route of administration is the largest contributor toward the market growth as most of the medications available in the market are in the form of tablets or pills and can be easily administered by patients on daily basis.

Key Benefits for Stakeholders

Thyroid Gland Disorder Treatment drugs manufacturers

Raw material suppliers

Industry associations

Government & Regulatory agencies and organizations

By Disease Type



By Drug Type




Imidazole-based Compound


By Administration




By Distribution Channel



Mail-order Pharmacy


By Region

North America




Key Market Players

Abbott Laboratories

Merck & Co. Inc.

AbbVie Inc.

Allergan Plc.

GlaxoSmithKline Plc

Lannett Company, Inc.

Mylan N.V.

Novartis AG

Pfizer Inc.


(A brief overview of 10 companies is also provided in the report.)

Research Methodology:

Genesis Market Insights follows in-depth Research Methodology focused on reducing deviation in the collected data. GMI offers the most precise evaluations and projection for the market numbers. GMI engages following Market Engineering techniques –

  1.      Raw Market Data is collected and compared with the Existing in-house Data on a broad front.
  2.      Both Bottom-Up and Top-Down approaches are analyzed for segmenting and estimating measurable aspects of the market.
  3.      To avoid bias, we filter the collected data collected from authenticated sources.
  4.      GMI has a well proven Statistical Modeling System for estimates and forecasts.
  5.      Further, the report findings are validated with the Industry Expert Panel on face to face or telephonic interviews.

Panelists are approached from Leading Enterprises across the value chain including manufacturers, suppliers, technology providers, domain experts and buyers so as to validate a thorough and balanced market overview.

Detailed customization is also available for you. Further, if the report listed above does not meet your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.

Table Of Content

1. Introduction

1.1 Market Vision

       1.1.1 Market Definition

       1.1.2 Market Scope

1.2 Limitations

1.3 Stakeholders

2. Research Methodology

2.1. Research Process

       2.1.1. Secondary Research

    Key Data from Secondary Research

       2.1.2. Primary Research

    Key Data from Primary Research

    Breakdowns of Primary Interviews

2.2. Market Size Estimation

       2.2.1. Bottom-Up Approach

       2.2.2. Top-Down Approach

       2.2.3. Annual Revenue Process

2.3. Data Triangulation 

2.4. Research Assumptions 

       2.4.1. Assumption

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Drivers

4.3. Restraints

4.4. Opportunities

4.5. Challenges

4.6. Regulations

4.7. Supply Chain/Value Chain Analysis

4.8. Patent & Standards

5. Industry Trends

5.1. Introduction

5.2. Porter’s Five Forces Analysis

       5.2.1. Threat of New Entrants

       5.2.2. Threat of Substitutes

       5.2.3. Bargaining Power of Buyers

       5.2.4. Bargaining Power of Suppliers

       5.2.5. Intensity of Competitive Rivalry

6. Thyroid Gland Disorder Treatment Market, By Disease Type

6.1 Hypothyroidism

6.2 Hyperthyroidism

7. Thyroid Gland Disorder Treatment Market, By Drug Type

7.1 Levothyroxine

7.2 Liothyronine

7.3 Propylthiouracil

7.4 Imidazole-based Compound

7.5 Others

8. Thyroid Gland Disorder Treatment Market, By Administration

8.1 Oral

8.2 Intravenous

8.3 Others

 9. Thyroid Gland Disorder Treatment Market, By Distribution Channel

9.1 Wholesaler/Distributor

9.2 Retailer

9.3 Mail-order Pharmacy

9.4 Others

10. Geographical Analysis

10.1. Introduction

10.2. North America

       10.2.1. U.S.

       10.2.2. Canada

       10.2.3. Mexico

10.3. Europe

       10.3.1. U.K.

       10.3.2. Germany

       10.3.3. France

       10.3.4. RoE

10.4. Asia Pacific

       10.4.1. South Korea

       10.4.2. China

       10.4.3. Japan

       10.4.4. RoAPAC

10.5. RoW

       10.5.1. Latin America

       10.5.2. Middle East and Africa

11. Company Profiles

(Business Overview, Financial Overview, Product write up, Recent Developments)

11.1 Abbott Laboratories

11.2 Merck & Co. Inc.

11.3 AbbVie Inc.

11.4 Allergan Plc.

11.5 GlaxoSmithKline plc

11.6 Lannett Company, Inc.

11.7 Mylan N.V.

11.8 Novartis AG

11.9 Pfizer Inc.

11.10 RLC LABS, Inc.

(A brief overview of 10 companies is also provided in the report.)

12. Competitive Analysis

12.1. Introduction

12.2. Market Positioning of Key Players

12.3 Competitive Strategies Adopted by Leading Players

        12.3.1. Investments & Expansions

        12.3.2. New Product Launches

        12.3.3. Mergers & Acquisitions

        12.3.4. Agreements, Joint Ventures, and Partnerships

13. Appendix

13.1. Questionnaire

13.2. Available Customizations 

13.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

* The list of tables and figures will be provided in the sample report.


No Content Available.



Related Reports